

FROM THE PRESIDENT

ESCI is now financially sound again, with a healthy group of new members to be elected at the next annual scientific meeting. The autumn meeting of the council was held in Toledo, Spain, so that we could plan the 28th Annual Scientific Meeting with the local organizers. During that meeting we had a long debate on the future of ESCI. All who have experience of ESCI feel that it is unique. We tried to identify that uniqueness and discussed how the Society should evolve.

The following qualities, it was concluded, make ESCI what it is.

1. It is a European Society: a historical tradition, which is now maturing, links European Science and medicine. This is expressed in an approach towards the intellectual pursuit of science that is different from other scientific blocks in the world. Furthermore, there is a common cultural and ethical tradition that influences how we fund science and publish results.
2. It is an interface Society: ESCI is the only European society that brings together both scientists and clinicians across a broad field of subjects. Since clinical medicine is based only upon science, a close communicating relationship between scientists and clinicians is of fundamental importance.

ESCI's Annual Scientific Meeting normally has more than a dozen workshops on a wide variety of scientific and clinical problems. The present state of understanding of biological sciences, especially at the intracellular and signalling level, means that research in one field might have direct relevance to another. Moving from workshop to workshop or among different poster sessions can be a unique source of stimulation and new ideas. Specialization has clearly had its place in advancing the technology of modern medicine. However, if it generates a restricted vision of biology, research may be impeded. Cross fertilization of ideas between organ systems and between the different disciplines of cell biology must be healthy in stimulating new research. For example, the recent advances in understanding the role of nitric oxide in biology and medicine could only have been achieved across such a wide range of physiology and pathology by scientists and clinicians who had cross-discipline understanding.

Some find the large European organ-based societies less fertile and less interesting than ESCI. Many such societies have grown so large then they are themselves in danger of breaking up into even more specialized societies.

There was much vigorous debate at the council meeting about the nature of the Annual Scientific Meetings of ESCI. The excellence of the science in the workshops and the value of the plenary lectures are key. The phagocyte group workshop has existed within the Annual Scientific Meeting for many years. It provides always excellent presentations and discussion that have brought richness to the Society. The phagocyte group now have a representative on council. The council believes it would be

desirable to attract other groups who at present have no 'home' to have the same relationship to ESCI that the phagocyte group enjoys. If that happened then ESCI would evolve from being a society guided by representations from national groupings towards a society based partly on nationalist representation and partly on a federation of research groups. I believe that such a combination would be the best way forward for ESCI. Since the council is generally in support of such a concept, the business meeting in Toledo will discuss such an evolution.

Several council members have been given tasks related to the revitalization of the Society. We must produce a plan to increase membership and ensure the Society grows and changes with the needs of changing science and an evolving Europe.

The European Journal of Clinical Investigation is a cornerstone of the Society. If it prospers, the Society will be helped to flourish. The new Editors-in-Chief and Editorial Board have dramatically improved the numbers of papers attracted making EJCI a journal that is growing in respect. Finally, the council meeting in Toledo discussed whether ESCI should seek a wider role in European science, for example in relation to the European Commission. There are arguments for and against. I hope the debate continues in Toledo in April.

The new council of ESCI has started vigorously. It is determined to lead the Society to a healthy future. I hope that you will debate the future with them at the business meeting of the 28th Annual Scientific Meeting of the Society in Toledo.

John F Martin

MACK-FORSTER AWARD 1994

Bo Angelin is 1994's winner of the Mack-Forster Award. Bo Angelin is 44 years old and currently professor of clinical medicine at Karolinska Institute in Sweden. He received his medical training at Uppsala University and his training in clinical Medicine in Huddinge University. For his accomplishments in medical science, in which he started to participate during his medical training, he was awarded by several Swedish medical societies.



Bo Angelin

The main body of Angelin's studies concern the characterization of regulatory mechanisms of cholesterol and lipoprotein metabolism, with particular emphasis to man. The principle approach has been to combine well-characterized clinical materials with state-of-the-art techniques, and confirmation of findings was possible with in vivo and in vitro models. His major contributions refer to (1) bile acid and cholesterol metabolism in hyperlipoproteinaemia, (2) regulation of lipoprotein metabolism, with particular emphasis on the influence of bile acids, hormonal treatment and malignancy, (3) enterohepatic

circulation and mechanisms responsible for the development supersaturated bile and (4) characterization of the biliary excretion of drugs. Significant findings included that a bile acid reabsorption defect can lead to VLDL overproduction in familial hypertriglyceridaemia. Furthermore, Angelin was among the first to demonstrate the importance of regulation of hepatic LDL receptors for lipid metabolism, to which a great deal of his latter effort was dedicated. In particular, he unraveled many aspects of the complex hormonal regulation of this LDL receptor. Moreover, important contributions were made to answering the question how hypertriglyceridaemia, lipid lowering medications and estrogen therapy can lead to formation of supersaturated bile and bile stones.

Bo Angelin is a very prolific writer. He participated in the publication of almost 250 original studies, many of these having appeared in outstanding journals. The Council of ESCI is honoured to present him this year's Mack-Forster Award at the 28th Annual Scientific Meeting in Toledo.

Hein A Koomans, honorary secretary-treasurer

WORKSHOPS

ESCI workshops bring the latest in science and create an atmosphere where scientists and physicians from several fields can share their common interest and learn from the ideas and data newly presented. The ESCI council has reviewed the workshop topics from 1989 to 1993 that have contributed to the success of the Annual Scientific Meetings. The permanent annual workshop on Phagocytes is one of the corner-stones of the Society. In addition, several recurrent topics appeared on the programme each year, for instance workshops on cardiovascular (dys-)function (n=9), diabetes mellitus (n=8), atherosclerosis (n=6), liver metabolism (n=5), hypertension (n=4), and topics from endocrinology (n=5), haematology (n=5), nephrology and neurology (n=4).

To promote the continuity of the scientific topics that will be discussed at the Annual Scientific Meetings, the council decided to gradually develop a number of permanent workshops that could be held on a yearly or two-yearly basis. In addition, we will try to have workshops on molecular medicine and clinical genetics in the near future as well as workshops on spectacular developments in basic science. Developments in these fields will have great impact on medicine and medical research and, therefore, deserve attention at our meetings. The first results of the new council policy should be visible at the Annual Scientific Meeting in Cambridge in April 1995. The council welcomes suggestions for workshop topics!

In Toledo, we will have excellent workshops on your favourite subject! In addition, entirely new topics are the workshops on molecular sciences, as well as a round table discussion devoted to the management of (European) science. We hope that you will visit several workshops and the interactive poster sessions as well as the plenary lectures that have been carefully selected. Our work is meant to result in your optimal participation to the meetings of the Society. Looking forward to seeing you in Toledo!

Tjerk W A de Bruin, honorary secretary-treasurer elect

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

The past twelve months have seen a further consolidation of the EJCI. This is manifested in a number of ways:

1. The time from acceptance to publication has been held tightly at no more than 4 months.
2. The number of papers submitted has risen and as a result the rejection rate is increasing with the greater ability to publish papers of increasing quality.
3. The ability to attract reviews of quality continues.
4. The number of manuscripts submitted for consideration as rapid communications increases.
5. The number of papers which referees feel merit commentary increases - an indicator of paper quality.
6. The increasing workload of specialist editors means that we have now had to increase the number of editors dealing with particular areas so that over the past year Dr Gareth Williams has been joined as a specialist editor for diabetes by Dr Julian Donckier (Brussels, Belgium) and Prof Galli has been joined by Prof Gerhard Kostner (Graz, Austria).
7. The increasing pressures on Prof Rudi Arnold and his wide variety of other commitments has necessitated his leaving the editorial board and we are delighted that Prof Richard Raedsch, a long standing and loyal supporter of the Society and former councillor and vice-president, has agreed to become the specialist editor in gastroenterology.
8. We are currently in the process of processing two further supplements for the journal and these will be clearly, provided the quality of their science meets our specification, provide the Society with much needed additional income.

The journal has clearly justified the decision to increase to monthly publication and has been rewarded through this change by greater interest in the European scientific community which is obviously keen to see the European equivalent of the North American Journal of Clinical Investigation grow and prosper. We have a long way to go. We continue to encourage manuscripts of quality and hope that members of the Society at the very least will see this as a journal worthy of publication of their best manuscripts.

Alan M McGregor, Editor-in-Chief EJCI

29TH ANNUAL SCIENTIFIC MEETING CAMBRIDGE, UNITED KINGDOM, 1995

The 29th Annual Scientific Meeting of the European Society for Clinical Investigation will be held in the University of Cambridge from 3rd - 6th April 1995, at the invitation of Professor Morris Brown. Prof Brown is Chairman of the Medical Research Society of the UK, and has arranged that this meeting will be a joint meeting of the two Societies. The MRS is similar to ESCI, but includes a section of 'Young Medical Scientists', who are the one hundred or so senior investigators aged less than 40 holding competitively awarded Senior Research Fellowships in the UK. One of the MRS sessions will consist of the annual Young Investigator Award Session in which the six best pieces of work by holders of Medical Research Council or other Training Fellowships are selected to compete for the Glaxo Young Investigator Medal.

The rest of the meeting will follow the usual ESCI style with a mixture of workshops, subspecialty poster sessions and

plenary lectures. The meeting will be held in the centre of the old University town of Cambridge, where the Colleges now offer a high standard of accommodation and lecture halls. The conference accommodation can cater for workshops from 20 to 400 participants. Invited plenary lecturers who have so far accepted include Prof Sydney Brenner, Prof Jacopo Meldolesi and Dr Salvador Moncada.

So far, the following workshops have been proposed:

1. Cell biology of phagocytes.
Organizer: to be announced
2. Allergens and clinical immunology.
Organizers: O Scheiner & C Gisinger (Vienna, Austria)
3. Platelet function.
Organizer: S Heptinstall (Nottingham, UK)
4. Physiology of liver transplants.
Organizer: S Keiding (Aarhus, Denmark)
5. Interactions between endocrine and immune systems.
Organizer: A Luger (Vienna, Austria)
6. Bone biology.
Organizer: A E Pontiroli (Milan, Italy)
7. Molecular medicine.
Organizer: T Cox (Cambridge, UK)
8. Renal transplantation and immunology.
Organizers: O Traudl & G Zlabinger (Vienna, Austria)
9. Novel aspects in physiopathology of reproduction.
Organizers: R Ivell & A Mukhopadhyay (Hamburg, Germany)
10. The epidermal growth factor family: physiological and therapeutic aspects.
Organizers: E Nexø (Aarhus, Denmark) & K D Brown (Cambridge, UK)
11. Body composition.
Organizer: R-J M Brummer (Maastricht, The Netherlands)
12. Fish oil and vascular disease III.
Organizers: R De Caterina (Pisa, Italy), S Endres (Munich, Germany), E B Schmidt (Aalborg, Denmark) & S Dalby Kristensen (Aarhus, Denmark)
13. Predictors of arterial thrombosis: focus on diabetes mellitus.
Organizers: M Mancini, G Di Minno (Naples, Italy), A Ceriello (Udine, Italy) & M Trovati (Turin, Italy)

Professor Brown can be contacted at:
Clinical Pharmacology Unit, Level 2 F&G Block,
Addenbrooke's Hospital,
Hills Road, Cambridge, CB2 2QQ, UK
telephone +44 (0)223 336743/telefax +44 (0)223 216893.

Prof Morris J Brown, local organizer

FINAL PROGRAMME 28TH ANNUAL SCIENTIFIC MEETING TOLEDO, SPAIN

20th - 23rd April 1994

Thursday 21st April 1994

- 09.00 - 09.15 *Opening ceremony of the 28th Annual Scientific Meeting*
A Gómez-Pan (Madrid, Spain)
J F Martin (London, UK)
- 09.15-10.00 *MERCK, SHARP & DOHME UPDATE LECTURE*
'Recent developments in human neuroendocrinology in health and disease'
G M Besser (London, UK)
Chairman: A Gómez-Pan (Madrid, Spain)

- 10.15 - 13.00 *WORKSHOPS (11.30 - 12.00 coffee break):*
10.15 - 13.00 Workshop 1:
Cell biology of phagocytes
10.15 - 13.00 Workshop 2:
Growth hormone in the adult: physiological and therapeutical aspects
10.15 - 13.00 Workshop 4:
Cytokines and autoimmune diseases
10.30 - 13.00 Workshop 6:
Oncogenes, cell growth and differentiation
10.15 - 13.00 Workshop 8:
Cellular and molecular basis for the prevention of atherosclerosis
10.15 - 13.00 Workshop 9:
Signal transduction and gene expression in vascular smooth muscle cell proliferation
10.15 - 13.00 Workshop 10:
Endothelin and cardiovascular risk factors: potential of endothelin antagonists
- 13.00 - 14.30 *Lunch and poster viewing subspecialty sessions*
- 14.30 - 15.15 *BOERHAAVE LECTURE*
'Regulation of integrin-mediated cell adhesive functions'
F Sánchez-Madrid (Madrid, Spain)
Chairman: A J Verhoeven (Amsterdam, The Netherlands)
- 15.30 - 18.00 *WORKSHOPS (16.30 - 17.00 tea break):*
15.30 - 18.30 Workshop 1:
Cell biology of phagocytes
15.30 - 18.30 Workshop 2:
Growth hormone in the adult: physiological and therapeutical aspects
15.30 - 18.00 Workshop 4:
Cytokines and autoimmune diseases
15.30 - 18.00 Workshop 5:
Arterial and arteriolar wall in diabetes mellitus.
Animal vs human studies
15.30 - 18.00 Workshop 6:
Oncogenes, cell growth and differentiation
15.30 - 18.30 Workshop 8:
Cellular and molecular basis for the prevention of atherosclerosis
15.30 - 18.00 Workshop 9:
Signal transduction and gene expression in vascular smooth muscle cell proliferation
15.30 - 18.00 Workshop 10:
Endothelin and cardiovascular risk factors: potential of endothelin antagonists
- 18.30 *End of Thursday's programme*

Friday 22nd April 1994

- 09.00 - 09.45 *BRISTOL-MYERS SQUIBB UPDATE LECTURE*
'Present and future prospects for transplantation'
M Yacoub (London, UK)
Chairman: S Keiding (Aarhus, Denmark)
- 10.00 - 13.00 *WORKSHOPS (11.30 - 12.00 coffee break):*
10.00 - 13.00 Workshop 1:
Cell biology of phagocytes
10.00 - 13.00 Workshop 5:
Arterial and arteriolar wall in diabetes mellitus.
Animal vs human studies
10.00 - 13.00 Workshop 6:
Oncogenes, cell growth and differentiation

- 10.00 - 13.00 Workshop 8:
Cellular and molecular basis for the prevention of atherosclerosis
- 10.00 - 13.00 Workshop 9:
Signal transduction and gene expression in vascular smooth muscle cell proliferation
- 13.00 - 14.30 *Lunch and poster viewing subspecialty sessions*
- 13.00 - 13.30 *Annual Business Meeting ESCI (members only)*
- 14.30 - 15.15 **LECTURE MACK-FORSTER AWARD 1994**
'Regulation of hepatic cholesterol metabolism in man: influence of genes, age and hormones'
B Angelin (Huddinge, Sweden)
Chairman: J F Martin (London, UK)
- 15.30 - 18.30 **SUBSPECIALTY POSTER SESSIONS**
(16.30 - 17.00 tea break)
Cardiovascular Medicine
Diabetes/Metabolism
Endocrinology
Gastroenterology/Liver
Haematology/Oncology
Hypertension
Nephrology
Respiratory Medicine
Rheumatology
- 15.30 - 18.30 **ROUND TABLE DISCUSSION**
(16.30 - 17.00 tea break)
'From basic research to clinical practice: a perspective from various European countries'
Organizers: F Pozo (Madrid, Spain) & P Lázaro (Madrid, Spain)
- 18.30 *END of Friday's programme*
- 21.00 *official congress DINNER*
(Parador Nacional, Toledo)

Saturday 23rd April 1994

- 9.00 - 09.45 **RENOLD MEMORIAL LECTURE**
'Insulin-like growth factor I mediates endocrine and opposes metabolic effects of growth hormone'.
E R Froesch (Zurich, Switzerland)
Chairman: A E Pontiroli (Milan, Italy)
- 10.00 - 13.00 **WORKSHOPS**
(11.30 - 12.00 coffee break):
- 10.00 - 13.00 Workshop 1:
Cell biology of phagocytes
- 10.00 - 13.00 Workshop 3:
Nitric oxide: recent developments and its significance for the clinical medicine
- 10.00 - 13.00 Workshop 5:
Arterial and arteriolar wall in diabetes mellitus.
Animal vs human studies
- 10.00 - 13.00 Workshop 6:
Oncogenes, cell growth and differentiation
- 10.00 - 13.00 Workshop 7:
Insulin like growth factor I (IGF-1) and metabolic effects
- 10.00 - 13.00 Workshop 11:
Body composition: methodological aspects and clinical relevance

- 13.00 - 14.30 *Lunch*
- 14.30 - 17.30 **WORKSHOPS (16.00 - 16.30 tea break):**
- 14.30 - 17.30 Workshop 1:
Cell biology of phagocytes
- 14.30 - 18.00 Workshop 3:
Nitric oxide: recent developments and its significance for the clinical medicine
- 14.30 - 17.30 Workshop 5:
Arterial and arteriolar wall in diabetes mellitus.
Animal vs human studies
- 14.30 - 17.30 Workshop 6:
Oncogenes, cell growth and differentiation
- 14.30 - 17.30 Workshop 7:
Insulin like growth factor I (IGF-1) and metabolic effects
- 14.30 - 17.30 Workshop 11:
Body composition: methodological aspects and clinical relevance
- 17.45 - 18.15 **SPECIAL ESCI LECTURE**
(supported by Eli Lilly)
'The polymerase chain reaction'
K B Mullis (La Jolla CA, USA), Nobel Prize Winner 1993
Chairmen: J F Martin (London, UK)
H Cortés-Funes (Madrid, Spain)
- 18.15 *End of meeting.*

Congress Venue

Hotel Beatriz
Carretera de Avila, km 2750
E-4500 TOLEDO, SPAIN
Telephone: +34 (0)25 22 22 11
Telefax:

Local Organizing Committee

A Gómez-Pan, J J Díez and
M D Rodríguez-Arno
(Madrid, Spain)

Organizing secretariat

Registration, enquiries,
information and technical exhibition:
ESCI Toledo 1994
Ms Isabel Candela
Serono Colloquia Spain
Apartado de Correos 113
E-28080 COSLADA MADRID, SPAIN

Telephone: +34 (0)1 563 4741
Telefax: +34 (0)1 562 5336

Travel Agency

Travel, accommodation and social programme:
Viajes Guadatur SA
Mr Joaquín Méndez
Avda Menéndez Pelayo 25
E-28009 MADRID, SPAIN

Telephone: +34 (0)1 409 7245
Telefax: +34 (0)1 409 3584

- the registration desk will be open on Wednesday from 14.00.
- participants of the meeting will receive the final programme at the registration desk.
- a welcome reception will be held on Wednesday evening 20th April at 20.00.

NEW COUNCILLORS 1994

For vice-presidency, Hein Koomans (Utrecht, The Netherlands) and Manuel de Oya (Madrid, Spain) are proposed.

Hereunder you will find the summarized curriculum vitae of the candidates nominated for councillorship. The councillors that will resign in 1994 are Marek Radomski (Beckenham, United Kingdom) and Giatgen Spinaz (Zurich, Switzerland). As in previous years, you can choose between two candidates per country on the enclosed ballot paper.

The ballot paper should be returned before 15th March 1994 to the Central Office of ESCI, Bolognalaan 40, 3584 CJ Utrecht. A simple majority vote will be decisive in each case.



Edouard Battegay

Edouard Battegay is currently jointly appointed to the Departments of Research and Internal Medicine at the University Hospital Basel as a senior research associate. His research activities focus on the endothelial cells, specifically in relation to the role of growth-regulatory molecules and cytokines in angiogenesis.



Thomas F Lüscher

His research activities focus on the role of endothelium-derived mediators in the regulation of vascular tone and platelet-vessel wall interaction, in particular also on the effects of lipoproteins and hypertension on these local regulatory mechanisms. In addition, in projects on the pathogenesis of coronary bypass graft disease, mechanisms of proliferation of human vascular smooth muscle cells are being studied.

Edouard Battegay is 37 years old and graduated in 1982 at the Medical School of the University of Basel, Switzerland. He began his postdoctoral training at the Departments of Pathology and Internal Medicine of the University Hospital in Basel. He completed his postdoctoral training from 1988 to 1991 at the Department of Pathology, University of Washington in Seattle, where he worked on the effects of different growth-regulatory molecules and cytokines on smooth muscle and fibroblast proliferation in the framework of a programme dealing with chronic inflammatory responses and atherosclerosis.

Thomas F Lüscher is 41 years old and graduated 1978 at the Medical Faculty of the University of Zurich, Switzerland. He began his postdoctoral training at the Department of Medicine of the University Hospital in Zurich and completed it at the Departments of Physiology (Cardiovascular Physiology) and Medicine (Cardiology) of the Mayo Clinic in Rochester MN, USA, between 1984 and 1986. At present, he is consultant in Cardiology and head



Marek Krzanowski

Marek Krzanowski is 35 years old and graduated 1983 from the Faculty of Medicine, Copernicus School of Medicine in Cracow. Ever since, he has been working at the Department of Medicine of this school. In 1988 he specialized in internal medicine. He wrote his doctoral thesis in 1993, on the influence of antiplatelet agents on thrombin generation in clotting blood, and was subsequently awarded the title of doctor in medicine. His research activities focus on angiology.



Krzysztof Sladek

Krzysztof Sladek is 38 years old and graduated in medicine from the Faculty of Medicine, University School of Medicine in Cracow. After completing his studies he joined the Division of Allergy and Immunology at the Department of Medicine of the above University, where at present he has a position as associate professor and is the director of the Bronchoscopy Unit. In 1983 he obtained the PhD degree in medicine from the University School of Medicine in Cracow. As a fellow he spent two years in Clinical Pharmacology at Vanderbilt University in Nashville, USA, and half a year as visiting scholar at the same Department, participating in the study on the role of eicosanoids in pathogenesis of asthma. His main research interest is the pathogenesis of aspirin-induced asthma (AIA). He is a member of the Coordinating Team of European Network on Aspirin-Induced Asthma, and Polish Society of Allergology and Pulmonology.

REVISED STATUTES

From a legal point of view the old statutes of the Society, drawn up at its founding in 1967, need revision. The reason is that over the past years all kinds of adjustments have been made and were approved during the annual business meetings, but were never officially amended in the statutes. The most important changes are:

- when the Society was founded, it was not possible to establish a society in the Netherlands for more than 29 years initially. In the meantime this rule has changed, but it means, of course, that the statutes have to be adjusted officially on this point.
- there is no longer an age limit for members or councillors.
- in this respect, emeritus membership does not longer exist.
- a councillor/officer may be elected subsequently to another office, even if membership of council expired several years before.
- the president serves for three years instead of one.
- the duties of secretary and treasurer are combined.

As mentioned, all these changes have been approved officially during previous annual business meetings and are, therefore, included in the new version of the statutes, which we herewith enclose for your approval. Please indicate your approval on the ballot paper, to be returned to the Central Office of ESCI before 15th March 1994.

Hein A Koomans, honorary secretary-treasurer

MEMBERSHIP

Membership of the Society is open to any person, irrespective of age, who has accomplished meritorious original investigation in clinical or allied sciences.

In addition, young scientists can apply for junior membership with a reduced membership fee. Eligibility:

- Any young scientist under the age of 30 can apply for junior membership of ESCI.
- Junior membership is for a maximum of three (3) years.
- Junior members receive the European Journal of Clinical Investigation and have the same financial benefits as full members.
- Junior members are not allowed to vote during the Annual Business Meeting and are not eligible to any office.
- Junior members can apply for full membership at any time.
- Junior members pay a membership fee which is about 40% lower than the full membership fee.
- If junior members do not fulfill the requirements for full membership within the period of three (3) years, their membership will be terminated.

Applications, both for full and junior membership can be sent to the Central Office. Application forms can be obtained from the Central Office.

Publication of this Newsletter is made possible by a generous gift of Merck, Sharp & Dohme.